GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocera Therapeutics Inc (NAS:OCRX) » Definitions » Operating Margin %

Ocera Therapeutics (Ocera Therapeutics) Operating Margin % : 0.00% (As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Ocera Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ocera Therapeutics's Operating Income for the three months ended in Sep. 2017 was $-6.08 Mil. Ocera Therapeutics's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, Ocera Therapeutics's Operating Margin % for the quarter that ended in Sep. 2017 was 0.00%.

The historical rank and industry rank for Ocera Therapeutics's Operating Margin % or its related term are showing as below:


OCRX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -168.78
* Ranked among companies with meaningful Operating Margin % only.

Ocera Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ocera Therapeutics's Operating Income for the three months ended in Sep. 2017 was $-6.08 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 was $-23.31 Mil.


Ocera Therapeutics Operating Margin % Historical Data

The historical data trend for Ocera Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocera Therapeutics Operating Margin % Chart

Ocera Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Operating Margin %
Get a 7-Day Free Trial Premium Member Only - -14,422.35 -7,236.95 -19,801.50 -4,249.59

Ocera Therapeutics Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18,060.53 -956.25 - - -

Competitive Comparison of Ocera Therapeutics's Operating Margin %

For the Biotechnology subindustry, Ocera Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocera Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocera Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ocera Therapeutics's Operating Margin % falls into.



Ocera Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ocera Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2016 is calculated as

Operating Margin %=Operating Income (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=-25.88 / 0.609
=-4,249.59 %

Ocera Therapeutics's Operating Margin % for the quarter that ended in Sep. 2017 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2017 ) / Revenue (Q: Sep. 2017 )
=-6.077 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocera Therapeutics  (NAS:OCRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ocera Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ocera Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocera Therapeutics (Ocera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
525 University Avenue, Suite 610, Palo Alto, CA, USA, 94301
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.
Executives
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Domain Partners Vi, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner

Ocera Therapeutics (Ocera Therapeutics) Headlines

From GuruFocus

Top 3 Insider Buys of the Week

By Monica Wolfe Monica Wolfe 07-19-2013

Three Insider Buys at 52-Week Lows

By Monica Wolfe Monica Wolfe 07-22-2014